(nasal spray, suspension influenza
vaccine (live attenuated, nasal))

Part One

Introduction

What is Fluenz Tetra
and how does it work?

Fluenz Tetra is a live attenuated intranasal influenza vaccine (LAIV) that
is administered as a nasal spray.

Fluenz Tetra contains live virus, which induces an immune response
that resembles the response after natural infection.1

  • Attenuated means that the live flu virus strains in Fluenz Tetra are weakened.2 When a person is given Fluenz Tetra, the immune system produces its own protection against the flu virus1
  • Fluenz Tetra vaccine viruses are grown in chicken eggs
  • The vaccine targets strains of flu virus each year that are aligned with the annual recommendations by the WHO2,3
 

Mode of action

Replication of the vaccine:

The live flu virus strains in Fluenz Tetra are cold-adapted, temperature-sensitive, and weakened.1,2 As a result, they replicate in the nasopharynx.2

Immune status is achieved after 14 days:3

Live flu virus strains induce protective immunity.4 The strains in Fluenz Tetra are updated every year to align with WHO recommendations.2

 

Which influenza strains does Fluenz Tetra contain?

New strains of influenza virus emerge when changes in the viral RNA occurring during replication alter the type of proteins present on its surface, i.e. changing the ‘appearance’ of the virus.1 When this happens, the body finds it hard to recognise, and therefore cannot fight it as effectively.1

The World Health Organisation (WHO) globally monitors influenza and, based on this analysis, recommends twice annually which strains should be included in influenza vaccines for the Northern and Southern hemisphere influenza seasons.2 The strains included for the 2013/2014 season are:

  • A/California/7/2009 (H1N1)pdm09-like strain
  • A/Victoria/361/2011 (H3N2)-like strain
  • B/Massachusetts/2/2012-like strain
View
Prescribing Information
View
References
View
References

The content in this e-learning module is based on the
Summary of Product Characteristics for Fluenz Tetra
unless otherwise stated

  1. Cox RJ et al. Scand J Immunol. 2004;59(1):1-15.
  2. Department of Health. Immunisation Against Infectious Disease. (The Green Book.) Chapter 19: Influenza. London: The Stationery Office. April 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/796886/GreenBook_Chapter_19_Influenza_April_2019.pdf.
  3. World Health Organization. Influenza. Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. 21 March 2019. https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/.

The content in this e-learning module is based on the
Summary of Product Characteristics for Fluenz Tetra
unless otherwise stated

  1. Vesikari T et al. Pediatr Infect Dis J. 2006;25(7):590–595. doi: 10.1097/01.inf.0000220229.51531.47.
  2. Department of Health. Immunisation Against Infectious Disease. (The Green Book.) Chapter 19: Influenza. London: The Stationery Office. April 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/796886/GreenBook_Chapter_19_Influenza_April_2019.pdf.
  3. Mohn KG et al. Hum Vaccin Immunother. 2018;14(3):571-578. doi: 10. 1080/21645515.2017.1377376.
  4. Murphy BR, Coelingh K. Viral Imm. 2002;15(2):295-323. doi: 10.1089/08828240260066242.